Young Therapeutics is a privately held biotechnology company started by Professor Lindon Young from the Philadelphia College of Osteopathic Medicine, focused on the identification and development of novel, first-in-class treatments for ischemia/reperfusion (I/R) injury. Young Therapeutics is dedicated to finding clinically meaningful and effective treaments for I/R in the settings of heart attack, and organ transplantation (orphan indications).

In 2015, Young Therapeutics obtained the exclusive worldwide rights to the patent estate for the YT compound portfolio from the Philadelphia College of Osteopathic Medicine.